Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
What is TRICON?
Each TRICON™ Capsule contains:
Special liver-stomach concentrate
(containing intrinsic factor). . . . . . . . . . . . . . . . 240 mg
Vitamin B12 (activity equivalent) . . . . . . . . . . . .15 mcg
Iron, elemental (ferrous fumarate) . . . . . . . . . .110 mg
Vitamin C (ascorbic acid) . . . . . . . . . . . . . . . . . 75 mg
Folic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.5 mg
with other factors of vitamin B complex present in the liver-stomach concentrate.
What does TRICON look like?
What are the available doses of TRICON?
Sorry No records found.
What should I talk to my health care provider before I take TRICON?
Sorry No records found
How should I use TRICON?
TRICON™ is a multifactor preparation effective in the treatment of anemias that respond to oral hematinics, including pernicious anemia and other megaloblastic anemias and also irondeficiency anemia. Therapeutic quantities of hematopoietic factors that are known to be important are present in the recommended daily dose.
One capsule twice a day. (Two capsules daily produce a standard response in the average uncomplicated case of pernicious anemia.)
What interacts with TRICON?
Sorry No Records found
What are the warnings of TRICON?
Sorry No Records found
What are the precautions of TRICON?
Sorry No Records found
What are the side effects of TRICON?
Sorry No records found
What should I look out for while using TRICON?
Hemochromatosis and hemosiderosis are contraindications to iron therapy.
What might happen if I take too much TRICON?
How should I store and handle TRICON?
Store at 25° C (77° F); excursions permitted to 15° - 30° C (59° - 86° F). See USP Controlled Room Temperature. Protect from light and moisture.TRICON™ Capsules are opaque brown NDC 63044-0635-10 Unit Dose Packs containing 10 capsules per card. 100 capsules.Storage:Manufactured ForNnodum Pharmaceuticals by Contract Pharmacal Corporation135 Adams Avenue Hauppauge, New York 11788TRICON™ Capsules are opaque brown NDC 63044-0635-10 Unit Dose Packs containing 10 capsules per card. 100 capsules.Storage:Manufactured ForNnodum Pharmaceuticals by Contract Pharmacal Corporation135 Adams Avenue Hauppauge, New York 11788TRICON™ Capsules are opaque brown NDC 63044-0635-10 Unit Dose Packs containing 10 capsules per card. 100 capsules.Storage:Manufactured ForNnodum Pharmaceuticals by Contract Pharmacal Corporation135 Adams Avenue Hauppauge, New York 11788
Chemical StructureNo Image found
Factor: when secretion of intrinsic factor in gastric juice is inadequate or absent (e.g., Addisonian pernicious anemia or after gastrectomy), vitamin B12 in physiologic doses is absorbed poorly, if at all. The resulting deficiency of vitamin B12 leads to the clinical manifestations of pernicious anemia. Similar megaloblastic anemias may develop in fish tapeworm () infection or after a surgically created small bowel blind loop; in these situations, treatment requires freeing the host of the parasites or bacteria that appear to compete for the available vitamin B12. Strict vegetarianism and malabsorption syndromes may also lead to vitamin B12 deficiency. In the latter case, parenteral therapy or oral therapy with so-called massive doses of vitamin B12 may be necessary for adequate treatment of the patient.
Potency of intrinsic factor concentrates is determined physiologically, i.e., by their use in patients with pernicious anemia. The liver-stomach concetrate with intrinsic factor and the vitamin B12 contained in two TRICON™ Capsules provide 1½ times the minimum amount of therapeutic agent that, when given daily in an uncomplicated case of pernicious anemia, will produce a satisfactory response and relief of anemia and symptoms.
Concentrates of intrinsic factor derived from hog gastric, pyloric, and duodenal mucosa have been used successfully in patients who lack intrinsic factor.
It is apparent that in vitamin B12 deficiency (e.g., pernicious anemia) lack of this vitamin results in impaired utilization of folic acid. There are other evidences of the close folic acid-vitamin B12 interrelationship: (1) B12 influences the storage, absorption, and utilization of folic acid, and (2) as a deficiency of B12 progresses, the requirement for folic acid increases. However, folic acid does not change the requirements for vitamin B12.
Each TRICON™ (hematinic concentrate with intrinsic factor) Capsule furnishes 110 mg of elemental iron (as ferrous fumarate) to provide a maximum response.
Non-Clinical ToxicologyHemochromatosis and hemosiderosis are contraindications to iron therapy.
Additive adverse effects resulting from cholinergic blockade may occur when hyoscyamine sulfate is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
Antacids may interfere with the absorption of hyoscyamine sulfate. Administer hyoscyamine sulfate before meals; antacids after meals.
Anemia is a manifestation that requires appropriate investigation to determine its cause or causes.
Folic acid alone is unwarranted in the treatment of pure vitamin B12 deficiency states, such as pernicious anemia. Folic acid may obscure pernicious anemia in that the blood picture may revert to normal while neurological manifestations remain progressive.
As with all preparations containing intrinsic factor, resistance may develop in some cases of pernicious anemia to the potentiation of absorption of physiologic doses of vitamin B12. If resistance occurs, parenteral therapy or oral therapy with so-called massive doses of vitamin B12 may be necessary for adequate treatment of the patient. No single regimen fits all cases, and the status of the patient observed in follow-up is the final criterion for adequacy of therapy. Periodic clinical and laboratory studies are considered essential and are recommended.
Rarely, iron in therapeutic doses produces gastrointestinal reactions, such as diarrhea or constipation. Reducing the dose and administering it with meals will minimize these effects in the iron-sensitive patient.
In extremely rare instances, skin rash suggesting allergy has been noted following the oral administration of liver-stomach material. Allergic sensitization has been reported following both oral and parenteral administration of folic acid.
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
ProfessionalClonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
InteractionsA total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).